

Method and Means for the Determination of Defined States or Modifications in the Mucus of the Uterus or in the Epithelium of Other Organs

The invention relates to method and means for determining defined states or modifications in the mucous membrane of the uterus or in the epithelium of other organs, in particular for diagnostics of pregnancy and its dysfunctions as well as diagnostics of the onset of labor and for determining optimal implantation conditions within the uterus, and the diagnostics of physiological and pathological epithelium states (carcinoma). Field of application is medicine, in particular, gynecology with the specific areas of reproductive medicine and obstetrics.

Human chorionic gonadotrophin (hCG) is a glycoprotein and is comprised of two subunits α hCG and β hCG that are non-covalently bonded (1). For the subunit α hCG a gene is known (chromosome 6q21.1-q 23). For the subunit β hCG there are 7 genes β 8, β 7, β 6, β 5, β 3, β 1 and β 2 known (chromosome 19q13.3).

During pregnancy, large amounts of hCG dimer and free α hCG and β hCG molecules are formed by the trophoblast in the uterus and secreted into the blood. Embryonic trophoblastic tissue expresses almost exclusively hCG β 5, β 8, and β 3. These β hCG subunits are therefore also referred to as trophoblastic β hCG (t β hCG) or type II β hCG.

However, in some non-trophoblastic tissues, hCG or its subunits are also expressed in minimal quantities (2-6). Non-trophoblastic tissue, for example, mamma tissue, lung tissue, prostate tissue, bladder tissue, colon tissue, express almost exclusively hCG β 7 and β 6. These β hCG subunits are therefore referred to as non-trophoblastic β hCG or type I

β hCG (7).

In the blood of healthy humans who are not pregnant hCG concentrations of hCG up to 1,000 pg/ml and of β hCG up to 100 pg/ml are therefore observed (8, 9). Higher β hCG serum values indicate a gonadal or non-gonadal tumor and indicate an unfavorable prognosis as described in connection with lung carcinoma, bladder carcinoma, prostate carcinoma, colon carcinoma, kidney cell carcinoma or mamma carcinoma (5, 10-14).

while the subunits of the type II β hCG (β 5, β 8, and β 3) contain at position 117 (exon 3) of the amino acid sequence an aspartate (Asp, D), the type I β hCG (β 7 and β 6) contains alanine (Ala, A) at position 117. The β hCG gene β 6 is an allele of β 7 with differences in the 5'-non-translating sequence of the promoter gene (exon 1) and in the translating sequence (exon 2) of the β hCG subunit. Only the genes β 8, β 7, β 6, β 5, and β 3 code and express a β hCG protein molecule of 145 amino acids (exon 2 and exon 3). The genes hCG β 1 and β 2 can be transcribed also in some tissues but code a protein of only 132 amino acids with different sequences relative to β hCG (15-17).

The hCG molecule is well-characterized by known standard preparations of up to now 24 monoclonal hCG antibodies of the International Society of Oncodevelopmental Biology and Medicine (ISOBM) that recognize different defined epitopes on the α hCG subunit (α 1- α 7, n=7), on the β hCG subunits (β 1- β 9, n=9), on the β hCG core fragment (cf β 10-cf β 13, n=4), and also conformation-dependent epitopes of the intact $\alpha\beta$ heterodimer ($\alpha\beta$ 1- $\alpha\beta$ 4, n=4) specifically and with high epitope affinity (18-20).

The antibodies recognize preferred epitopes in the spatial

amino acid arrangement of the hCG molecule, i.e., of its tertiary and quaternary structure (17; Fig. 2 and Fig. 3 in 18). For this reason, for the preparation of hybridomas for the formation of the aforementioned monoclonal ISOBM antibodies WHO reference hormone preparations of the hCG, respectively, β hCG of the International Federation of Clinical Chemistry (IFCC) are used as much as possible as adequate antigenic determinants. Exceptions are the β hCG epitopes β 8 (AS 137 to 144) and β 9 (AS 109 to 116) of the C-terminal end (CTP) as well as a portion of the β hCG epitope β 1 (AS 1 to 10) of the N-terminal end of β hCG that represent an immunological antigen potential (21, 22) at the edge of the surface of the hCG dimer in cystine knot structure and substantially unaffected by the tertiary structure. This linear β hCG epitope sections about AS 1-16, AS 108-123, and AS 137-144 are recognized by monoclonal β hCG antibodies that are produced by the method of carrier-bonded synthetic peptides as antigenic determinants of the ISOBM antibodies (18, 19, 21, 22).

For the antigen region β 1, β 8, β 9 of the β hCG molecule (Fig. 3 in 18) ISOBM β hCG antibodies have already been prepared; they are based on the known amino acid sequence of the trophoblastic (or placenta) β hCG subunit. Especially the amino acid sequence about 108-123 of the C-terminal end of β hCG (β hCG-CTP) characterized as epitope β 9 shows a high antigenicity (21). To a somewhat lesser degree, this also holds true for the amino acid sequence about 1-16 as a part of the epitope β 1 (23). Antibodies generated with synthetic peptides against these peptide sequences recognize specifically the native trophoblastic β hCG subunit (18, 19, 21, 23, 24).

In the past, the different studies have been undertaken with the goal to detect by means of semi-quantitative methods (5,

12, 13, 25) β hCG transcripts in different normal and neoplastic tissues of non-trophoblastic origin. These methods show that β hCG is transcribed in normal placenta (26), healthy testes (6), but also neoplastic testes (27) and neoplastic bladder tissue (28). However, in these studies no differentiation is being made between type I β hCG and type II β hCG.

For this purpose, different test kits have been proposed that function with different epitope specificity (29) and that enable the determination of the trophoblastic total molecule $\alpha\beta$ hCG (total hCG) or of the individual subunits of the molecule β hCG and α hCG (18). Especially for pregnancy tests and diagnostics of hydatid moles and choriocarcinoma methods have been developed in which the heterodimer trophoblastic total molecule hCG alone (total thCG) or the sum with the free subunit of the trophoblastic β hCG (total t β hCG plus t β hCG) or the free t β hCG subunit alone is determined. The heterogeneity of the trophoblastic hCG in biologic material (intact $\alpha\beta$ heterodimer, free α hCG, free t β hCG, f β hCG core fragment, nicked thCG, nicked β hCG) relative to bonding on the respectively employed antibodies, make a precise determination and standardization of a possible detection method for the epithelial hCG more difficult. An additional heterogeneity of the t β hCG determination in the secretory cycle phase and early pregnancy can occur to a minimal degree also between the four native hyperglycosylated or desialylated hydrocarbon side chains of the C-terminal end (CTP) of t β hCG (amino acid 120 to 145) as they have been observed in differentiated forms in the early to middle stages of a pregnancy and for choriocarcinoma in trophoblastic β hCG (31, 33-37).

The pregnancy tests known so far have the disadvantage that they often render false positive results.

The currently known pregnancy tests can evaluate only unsatisfactorily reduced hCG concentration measurements during the extra uterine pregnancy (ectopic pregnancy) or hCG titer in female patients after IUD insertion under the aspect of changed uterine secretion behavior (38, 39).

The phenomenon that a pregnancy test in the blood is positive for hCG, even though no pregnancy or no tumor in the genital tract is present, is referred to as a phantom hCG. The current discussion of phantom hCG values is based on the fact that this phenomenon is derived from abnormal interaction between the test and irregular antibodies contained in the blood sample of the female patient (54).

It is an object of the invention to provide method and means that enable detection of defined states or modifications in the mucous membrane of the uterus (endometrium, decidua) but also in the epithelium of other organs. The method and the means should enable in particular the determination of optimal implantation conditions in the uterus and a reliable diagnostics of a pregnancy and their dysfunctions as well as the beginning of the birthing process.

The invention is based on the scientific recognition that in the endometrial tissue and the decidual epithelial β hCG subunits are expressed that differ in several amino acid positions from the known trophoblastic β hCG subunits.

The nucleotide sequence and protein sequence for the endometrial β hCG subunits is represented for the first time in SEQ ID No. 7 and SEQ ID No. 10 (e β hCG or endo).

The β hCG subunits expressed in the endometrial and the decidual epithelium are referred to in the following as

endometrial β hCG (e β hCG). Our results indicate that the e β hCG represents an endometrial variant of the subunits β 7 and β 6, while trophoblastic β hCG is formed exclusively of the subunits β 5, β 8, and β 3.

The following differences of the e β hCG to the known trophoblastic β hCG (t β hCG) have been found:

One variant of aspartate (t β hCG) in the amino acid position 117 of the C-terminal end of β hCG (β hCG-CTP) to alanine (e β hCG).

Further variants were found in position 2 and position 4 of the exon 2. The trophoblastic β hCG (t β hCG) has at position 2 lysine and at position 4 proline. The endometrial β hCG (e β hCG) has at position 2 arginine and at position 4 methionine.

In the following, the term endometrial β hCG (e β hCG) is to be understood as a β hCG that has at least one of the aforementioned variants.

Fig. 1 shows an alignment of the sequence of the e β hCG (endo) with the sequences of the trophoblastic β hCG subunit t β hCG β 5 and the known non-trophoblastic β hCG subunits β 6 and β 7 as well as the pituitary β LH β 4 (β subunit of the luteal hormone).

The nucleotide sequence of the endometrial e β hCG (SEQ ID No. 7) differs also from the known non-trophoblastic β hCG subunits β 7 (SEQ ID No. 5) and β 6 (SEQ ID No. 6), in particular in the promoter gene of the exon 1 but also in exon 2 at the expression location of the amino acid positions 2 and 4 (Fig. 1). In the amino acid sequence (SEQ ID No. 10) resulting from gene expression, the endometrial e β hCG

presents itself as a variant of the epithelial type I β hCG of the β hCG β 7 protein (SEQ ID No. 9) with three different amino acids at positions 2, 4 and 117 between the endometrial or decidual e β hCG and the conventional trophoblastic t β hCG (SEQ ID No. 8). The amino acid sequence of the endometrial e β hCG (SEQ ID No. 10) differs significantly (Fig. 1) relative to the sequence of the pituitary β LH β 4 (SEQ ID No. 11).

Furthermore, the invention is based on the scientific recognition that the reason for the false positive results known in the case of prior art tests is that they cannot differentiate between the trophoblastic secretion output of the embryo in the form of the t β hCG and the secretion output that result from the secretion transformation and uterine decidual formation of the endometrium as well as during epithelial differentiation (e β hCG).

Method:

Based on this recognition, the object is solved according to the invention by a method for determining defined states or modifications in the mucous membrane of the uterus or in the epithelium of other organs in that in a body liquid sample and/or tissue sample the concentration of endometrial β hCG or non-trophoblastic β hCG is determined specifically. The term specific e β hCG determination is to be understood in that a differentiation is made between endometrial β hCG and trophoblastic β hCG.

The determination of concentration is realized preferably in a sample (in the form of secretions, perfusion liquid, cells or tissue) of peripheral blood, serum, menstrual blood, lochia, amniotic fluid, urine, saliva, eye chamber fluid as well as secretions of the urogenital tract (including uterus, cervix, vaginal samples), of the gastrointestinal (including

mucous membrane of the mouth) and of the respiratory tract as well as of the central nervous system (incl. liquor).

Preferably, in the method according to the invention, in addition to the concentration of endometrial β hCG or non-trophoblastic β hCG also the concentration of trophoblastic β hCG (t β hCG), total β hCG or total hCG is determined.

The determination of trophoblastic β hCG (t β hCG), total β hCG, or total hCG is carried out preferably according to known methods (18, 19, 21, 22, 23, 24, 29, 30, 31, 54).

Since these methods known in the art do not differentiate between t β hCG and ehCG, the specific determination according to the invention of e β hCG for the first time also enables a determination whether the t β hCG determined with these tests is indeed t β hCG and how high the proportion of t β hCG and e β hCG is.

The proportion of t β hCG results from the concentration of the total hCG / β hCG or the total hCG minus the measured e β hCG or the non-trophoblastic β hCG.

Advantageously, the method according to the invention is suitable in particular for diagnosis of the readiness (receptivity) of the mucous membrane of the uterus for a fertilized egg and enables thus the determination of optimal implantation conditions in the uterus.

It was found that the expression of e β hCG in the mucous membrane of the uterus (endometrium) is required in order to enable the successful implantation of the fertilized egg. The beginning of the e β hCG or of ehCG is an indication for the receptivity of the mucous membrane of the uterus for a fertilized egg.

The diagnosis of the receptivity of the mucous membrane of the uterus (implantation condition) for a fertilized egg is carried out preferably prospectively in that from a female patient in the early luteal phase tissue is removed from the endometrium or from the cervical mucous membrane (mucous membrane of the mouth), or a secretion of the vagina, the cervix, or the uterus, or serum, plasma and peripheral blood is removed; in this sample, the non-trophoblastic or endometrial β hCG concentration is determined. Based on the level of the determined expression it is then possible to draw conclusions in regard to the current receptivity of the uterus for an embryo or a prognosis for the following cycle.

For this purpose, preferably several days after ovulation cells are removed by means of a mini catheter from the uterus cavity, by means of a cotton swap from the cervical channel, or by means of a wooden spatula from the mucous membrane of the mouth or peripheral EDTA or heparin blood is taken. In the taken cells the non-trophoblastic or endometrial β hCG concentration is determined.

For the prospective diagnostics of the embryo receptivity in the early secretion phase of the actual cycle, preferably tissue samples of the endometrium, the endocervix, the mucous membrane of the mouth or other select epithelia as well as cervical/vaginal secretions or endometrial secretions after smear or as a perfusate are examined in order to determine the quality of the secretory transformation to be expected and receptivity of the endometrium (for example, for the determination of an embryo transfer after in-vitro fertilization in a hormonally stimulated cycle).

Based on the information of implantation conditions in the preceding cycle, a prognosis for the implantation conditions,

i.e., receptivity of the uterus for the fertilized egg or an embryo, in the following cycle can be made.

A further preferred use of the method is therefore the application for retrospective diagnostics of the receptivity of the mucous membrane of the uterus. The term retrospective implantation diagnostics in the context of the present invention is to be understood as the detection of the secretory transformation of the endometrium of the preceding cycle in order to make projections for the receptivity of the subsequent cycle. They exhibit an undisturbed fallopian tube/uterus relationship that is timely and functionally appropriate. The method according to the invention therefore can supplement or replace the invasive method of a Pap smear in regard to its information contents.

By means of the evaluation and quantification of the specific epithelial endometrial hCG secretion (ehCG) in bodily fluids and cell (tissue) homogenates of the early, middle and late secretion phase of the menstrual cycle, optimal implantation conditions as well as possible fertilization dysfunctions can be determined prospectively as well as retrospectively under the aspect of endometrial diagnostics and therapy control.

In the retrospective diagnostics of the receptivity of the mucous membrane of the uterus, the same method as for a prospective (preparatory) implantation diagnostics can be carried out in principle. Preferably, the analysis of the β hCG concentration is carried out in a sample of menstrual blood or a sample of cells contained in the menstrual blood.

In the menstrual blood, sufficient cells of the endometrium are present that enable a determination of the β hCG concentration.

The advantage of the retrospective diagnostics in the menstrual blood relative to the afore described prospective method resides in that it is not invasive. Neither peripheral blood nor a tissue sample of the uterus must be taken. In spite of this, with this method a timely and functionally appropriate conversion of the endometrium in the secretion phase of the cycle can be detected which is at the same time an expression of an undisturbed regulation function at the level of hypothalamus/pituitary gland, ovaries, and uterus.

Menstrual blood like peripheral blood can be used, after centrifugation for the purpose of separating cells and stroma, for the direct measurement of endometrial β hCG secretion with specific antibodies in the ELISA test. The menstrual blood is taken after a spontaneous cycle, after hormone therapy, after in-vitro fertilization (IVF), and embryo transfer (ET) without successful implantation as well as in case of preparatory diagnostics of the cycle in the case of female patients wanting children and female patients with gynecological diseases such as myoma, endometriosis, endometrial carcinoma and cervix carcinoma. The parallel harvesting of peripheral blood simultaneous to heparin blood or serum is mandatory for excluding an increased unspecific serum hCG value.

When the concentration of the $e\beta$ hCG or non-trophoblastic β hCG in menstrual blood is increased relative to the concentration in the peripheral blood, a local formation in the endometrium can be assumed. A high $e\beta$ hCG concentration is the expression of a physiological function of the endometrium and lack of or a low $e\beta$ hCG concentration is the expression of a pathological function of the endometrium. Since the peripheral blood does not contain $t\beta$ hCG, a conventional β -hCG-assay (inter alia ELISA, MEIA - see literature citations 18, 19, 21, 22, 23,

24, 28, 29, 30, 54) that does not differentiate between t β hCG and e β hCG can be used for the determination in the peripheral blood alone.

In the prospective or retrospective diagnosis of the receptivity of the mucous membrane of the uterus a differentiation between endometrial and trophoblastic β hCG is not mandatory because there is no pregnancy yet and therefore an expression of t β hCG by a trophoblast is precluded. The invention comprises therefore also the use of a method in which the concentration of total hCG / β hCG or total β hCG is determined for diagnosis of the receptivity of the mucous membrane of the uterus for a fertilized egg. In this method, the determination of hCG is realized preferably with antibodies that recognize $\alpha\beta$ hCG, the known β 7, β 6, or β 6 hCG subunits. These antibodies must not be specific for e β hCG, i.e., they can also recognize t β hCG.

As such an antibody, a known polyclonal or monoclonal anti $\alpha\beta$ hCG or an anti β hCG antibody is used preferably. This antibody recognizes preferably an epitope selected from the group of the epitopes β 1 to β 9 (especially preferred β 2 to β 8) of the β hCG subunit, of the epitopes cf β 1 to cf β 13 on the β hCG core fragment and the confirmation-dependent epitopes $\alpha\beta$ 1 to $\alpha\beta$ 4 of the intact $\alpha\beta$ heterodimer according to the classification of the International Society of Oncodevelopmental Biology and Medicine (ISOBM) (18-20). Such antibodies can be purchased, for example, from the company BIOTREND Chemikalien GmbH, Cologne, Germany, or Serotec, Düsseldorf, Germany.

The diagnosis of the receptivity of the mucous membrane of the uterus for a fertilized egg is carried out preferably retrospectively with a sample of menstrual blood or a sample of cells contained in the menstrual blood. For a parallel

removal of peripheral blood, the measured hCG value is negligible relative to the hCG in the menstrual blood.

During menstruation, a pregnancy and thus an expression of t β hCG by a trophoblast can be excluded. A differentiation between e β hCG and t β hCG can therefore be carried out in the menstrual blood even without specific e β hCG detection.

The invention therefore also concerns a method for determining defined states or modifications in the mucous membrane of the uterus or in the epithelium of other organs in which the determination of total hCG, β hCG or total hCG/ β hCG concentrations is realized, as described above, in a sample of menstrual blood.

Contrary to the generally accepted belief it is not t β hCG that is the first β hCG to be detected in early pregnancy but the endometrial or decidual e β hCG.

Advantageously, the method according to the invention is also suitable to improve the efficacy of already known pregnancy tests. In the known pregnancy tests, only β hCG is determined that is generated by trophoblast or the unspecific total β hCG is determined. Since ehCG is generated already in the well established secretion phase of the endometrium and with the embryo implantation the decidual hCG is released increasingly, it is possible with the method according to the invention to provide a pregnancy diagnosis at an early point in time because, as a result of the early pregnancy occurrence, the ehCG is released into the blood circulation by a flowum instead of being excreted to the exterior as in the case of menstruation.

Since the known tests also cannot provide information as to whether the trophoblast has implanted successfully in the

uterus, they often lead to false positive results.

In contrast to known pregnancy tests in which the heterogeneity of the β hCG is not taken into consideration, according to the invention the concentration of endometrial β hCG or non-trophoblastic β hCG is specifically determined. In this way, information is derived in regard to the secretion output and receptivity of the mucous membrane of the uterus which is a prerequisite for a successful pregnancy. The method according to the invention leads therefore to a more reliable pregnancy diagnosis relative to known methods. The method according to the invention enables also the differentiation between an extra-uterine pregnancy or an early pregnancy loss and an intra-uterine pregnancy. In the case of an intra-uterine implantation of the embryo, the expression of e β hCG is higher than in the case of an extra-uterine implantation. The diagnosis of an extra-uterine pregnancy is done preferably by analysis of a serum sample. A low concentration of e β hCG in the serum at normal t β hCG is a sign for extra-uterine pregnancy. In the case of early pregnancy loss e β hCG is present, but t β hCG expression is missing.

Preferably, for pregnancy diagnosis, in addition to the concentration of endometrial β hCG or non-trophoblastic β hCG, also the concentration of trophoblastic β hCG (t β hCG), total β hCG or total hCG is determined also in accordance with the afore mentioned known methods.

The specific determination according to the invention of e β hCG enables for the first time also information whether the β hCG determined by the known methods is indeed t β hCG and how high the proportion of t β hCG and e β hCG is. In this way, it can be reliably determined for the first time whether a pregnancy is actually present or not. A pregnancy is present

when thCG has been detected for sure. Since ehCG is of epithelial origin and originates from the woman, a short-term hCG detection according to the prior art after menstruation did not occur is not the same as an early pregnancy. According to the prior art, often early pregnancy losses are misinterpreted as pregnancy. The same holds true for the hCG detection in accordance with the prior art in the second half of the cycle in the case of women wearing a copper IUD. In this case, there is also no pregnancy; instead, the altered endometrium reacts with release of ehCG.

with the differentiated determination of concentration of the ehCG and its relation to thCG it is for the first time possible to differentiate diagnostically whether a pregnancy dysfunction is caused by a change of decidual or the trophoblastic embryonic/fetal unit.

The method according to the invention enables also the possibilities of monitoring the pregnancy during its course and to make a prognosis in regard to possible pregnancy dysfunctions or the success of a pregnancy.

An undisturbed pregnancy is characterized by high ehCG values in the peripheral blood and in the samples of the genital tract (Pap smear, secretion, tissue). When low ehCG values are present there is a risk of miscarriage. By means of the inventive method, the risk of miscarriage can be diagnosed early on and a therapy can be started immediately. Subsequently, the method can be used for therapy control. In this connection, the method according to the invention advantageously enables the differentiation between a dysfunction of the decidua from a trophoblastic/embryonic dysfunction when a miscarriage begins. When a trophoblastic/embryonic dysfunction is present, the t β hCG value is lower.

Other pregnancy dysfunctions such as intra-uterine growth retardation and preeclampsia exhibit non-physiological, i.e., lowered. ehCG values that can be diagnosed with the method according to the invention.

The determination of the ehCG in the serum and in samples of the genital tract (Pap smear, secretion, tissue) can be used advantageously for the screening in regard to premature birth and the determination of the onset of labor. Increased e β hCG values in the secretions of the urogenital tract, in particular, vaginal and cervical secretions, and lowered values in the serum indicate a premature birth or, at the end of pregnancy, the onset of labor.

The specific determination of the ehCG concentration in the amniotic fluid enables advantageously the diagnostics of the decidual function during pregnancy. After birth, the decidual function can be determined advantageously subsequently also by specific determination of the ehCG concentration in the lochia. A high e β hCG concentration is in both cases a sign for a healthy function of the decidua. A reduced t β hCG concentration however is an indication of a pathological pregnancy.

The method according to the invention for specific determination of e β hCG or of non-trophoblastic β hCG also is suitable for determining the effectivity of contraceptive method. Lack of, drop of or temporal displacement of the e β hCG secretion is in this connection a sign of the quality of the contraceptive potency and enables the classification of a method.

For this purpose, the e β hCG concentration in samples (secretion, rinsing liquid, cells, tissue) of the endometrium

is determined preferably by ELISA with e β hCG specific antibodies.

When no e β hCG is produced by the endometrium, this is a sign that the endometrium is not receptive for a fertilized egg. Therefore, there is protection against pregnancy.

The method according to the invention can advantageously be used also for differentiation between physiological and pathological epithelium states. In this connection, an epithelial ehCG expression or an expression of non-trophoblastic β hCG (β 7, β 6) indicates physiological conditions while the detection of t β hCG (β 5, β 8, β 3) in a cell or tissue sample is an indication of a pathological epithelial process, for example, a tumor, a beginning dedifferentiation or a beginning carcinogenic degeneration or a carcinoma.

Pathological epithelial processes that can be diagnosed by means of the method according to the invention in particular in this way are endometriosis, myoma, thyroid diseases as well as carcinoma of the endometrium, of the ovaries and of the peritoneum.

The determination of the e β hCG expression and the parallel determination of the total hCG/ β hCG or total hCG is carried out in this connection preferably in biological material of the desquamation of the endometrial tissue after separation of the epithelial cells from the stroma cells, the peripheral mononuclear blood cells and the mononuclear immune cells of the endometrial epithelium.

By means of the method according to the invention, it is thus possible to differentiate a proper differentiation of epithelium organs and a false differentiation and beginning

carcinogenic degeneration. This is possible because a differentiation is possible between the $\beta 7$ hCG and the tumor-specific $\beta 5$ hCG on the level of transcription and translation. The concentrations and their relations of both hCG types provide information in regard to the epithelial health or its dysfunctions in the sense of a de-differentiation. Also, the malignant potency and the prognosis of a tumor disease can be derived therefrom.

Because of the recognition that hCG is also an epithelial hormone that is secreted by the epithelium of the inner surface, the detection of hCG in the serum of healthy non-pregnant female patients and patients without detection of the tumor is not surprising. Presently, this inexplicable hCG detection in female patients/patients without pregnancy and tumor as a so-called phantom hCG is related to the presence of irregular antibodies. By means of the method according to the invention of the specific determination of e β hCG or non-trophoblastic β hCG, these cases of phantom hCG can be explained as a physiological variant of an epithelial functional output. By means of the method according to the invention a physiologically increased expression e β hCG or non-trophoblastic β hCG ($\beta 7$, $\beta 6$) can be differentiated from an increased t β hCG ($\beta 5$, $\beta 8$, $\beta 3$) expression in a carcinoma. Unnecessary chemotherapeutical treatments and long-term expensive monitoring of these patients are thus obsolete.

The determination of concentration of endometrial β hCG (e β hCG) is carried out semi-quantitatively or quantitatively.

In a preferred embodiment the concentration determination is realized with at least one antibody that recognizes specifically e β hCG or non-trophoblastic β hCG (t β hCG) by means of an ELISA, a dot-blot, or western blot assay, by an immunohistochemical method, flow cytometry or another known antibody based method. In an alternative embodiment, the determination of concentration of endometrial β hCG (e β hCG)

and the differentiation relative to trophoblastic β hCG is done at the level of RNA expression, for example, by known methods of RT-PCR or, for example, by hybridization with an oligonucleotide probe.

The invention comprises also the antibodies which recognize specifically e β hCG and non-t β hCG. The term antibody in the context of the present intention includes, in addition to monoclonal and polyclonal antibodies, also recombinant antibodies and fragments, for example, scFv (single chain fragments) and Fab fragments. Preferably, the antibody has a marker molecule, for example, biotin, dioxxygenin, or a fluorescent dye.

The e β hCG-specific antibodies according to the invention recognize preferably a hexa- to deca-peptide in the area of the amino acid position of 117 (SEQ ID No. 1) or in the area of the amino acid positions 2 and 4 (SEQ ID No. 3) of the sequence of the e β hCG (SEQ ID No 10). These e β hCG-specific epitope areas are identified as e β 9 (SEQ ID No. 1) and e β 1 (SEQ ID No. 3). From these epitope areas, the e β hCG-specific antibodies recognize an epitope which comprises amino acid position of 117 or amino acid positions 2 and 4, such as, for example,

Pro - Arg - Phe - Gln - **Ala** - Ser - Ser
117

or

Ser - **Arg** - Glu - **Met** - Leu - Arg - Pro -
2 4
3

The inventive e β hCG-specific antibodies however do not react with the corresponding t β hCG epitopes β 9 and β 1 of the corresponding areas (SEQ ID Nos. 2 and 4) of the sequence for

t β hCG (SEQ ID No. 8) such as, for example:

Pro - Arg - Phe - Gln - **Asp** - Ser - Ser
117

Ser - **Lys** - Glu - **Pro** - Leu - Arg - Pro -
2 4

The inventive antibodies are preferably generated by a peptide selected from the peptide sequence according to SEQ ID No. 1, 12, as well as 3 and 14 or their partial sequences and do not react with the control peptides for t β hCG according to SEQ ID No. 2, 13, as well as 4 and 15.

A further object of the invention is a test kit for determining defined states or modifications in the mucous membrane of the uterus or in the epithelium of other organs.

This test kit comprises at least one antibody that recognizes specifically e β hCG as well as optionally stabilizers, additional antibodies, for example, additional anti-hCG antibodies, secondary antibodies, standards, buffers, reagents for blocking free binding locations (for example, skim milk powder or bovine serum albumin (BSA)).

Preferably, the antibody of the diagnostic kits that recognizes specifically e β hCG is bonded to a solid support. Such a solid support, is, for example, an ELISA carrier, preferably made of polycarbonate, or in the case of a dot-blot or Western blot assay a film, preferably made of nitrocellulose.

The bonding of the antibody on the ELISA carrier enables advantageously performing a sandwich ELISA in which bonding of the e β hCG to the e β hCG-specific antibody is detected by a second anti-hCG antibody. The bonding of the antibody to the

ELISA carrier is achieved, for example, by incubation of the carrier with an antibody solution in 50 mmol per liter carbonate at a pH value of pH 8 to pH 9 for at least one hour and subsequent drying.

As a second anti-hCG antibody preferably a polyclonal or monoclonal anti- $\alpha\beta$ hCG or β hCG antibody is used which, in contrast to the inventive e β hCG-specific antibodies, recognizes the endometrial as well as the trophoblastic hCG.

This antibody recognizes preferably an epitope selected from the group of epitopes β 1 to β 9 (preferably β 2 to β 8) of the β hCG subunit of the epitopes cf β 1 to cf β 13 on the β hCG core fragment and the confirmation-dependent epitopes $\alpha\beta$ 1 to $\alpha\beta$ 4 of the intact $\alpha\beta$ heterodimer of the classification of the International Society of Oncodevelopmental Biology and Medicine (ISOBM) (18-20). Such antibodies can be purchased, for example, from the company BIOTREND Chemikalien GmbH, Cologne, Germany, or Serotec, Düsseldorf, Germany.

As a standard for e β hCG or as a negative control for t β hCG the test kit contains preferably e β hCG or peptides with an amino acid sequence of 6 to 15 amino acids from the area of the amino acid position 2 and 4 or in the area of the amino acid position of 117 of the sequence of e β hCG (SEQ ID No. 7), i.e., the epitopes e β 1 or e β 9, preferably peptides of the SEQ ID No. 1, 12, 3, 14 or their partial sequences, their solutions.

As a standard for t β hCG or as a negative control for e β hCG the test kit preferably contains t β hCG or peptides with an amino acid sequence of 6 to 15 amino acids of the area of the amino acid position 2 and 4 or in the area of the amino acid position of 117 of the sequence of t β hCG (SEQ ID No. 8), i.e., of the epitopes β 1 or β 9, preferably peptides of the SEQ ID No. 2, 13, 4, 15 or their partial sequences, their

solutions.

A further object of the invention are the isolated endometrial β subunits (e β hCG) of human chorionic gonotrophin (e β hCG) with the amino acids sequence according to SEQ ID No. 10 and the isolated gene sequence for e β hCG according to SEQ ID No. 7 and the use of sequences as marker for the pregnancy diagnosis or for diagnoses of the receptivity of the mucous membrane of the uterus for the fertilized egg. Object of the invention are also the isolated peptide sequences according to SEQ ID No. 1, 3, 12, and 14.

The invention concerns also the use of the e β hCG-specific antibody according to the invention, the isolated peptide sequence according to SEQ ID No. 1, 3, 12 and 14, and the test kit according to the invention for pregnancy diagnosis or for diagnosis of the receptivity of the mucous membrane of the uterus for the fertilized egg.

The invention will be explained with the following embodiments in more detail without being limited to these embodiments.

Embodiment 1: producing a polyclonal antibody specific for the epithelial endometrial hCG molecule (e β hCG) to the β hCG epitope β 9 on the C-terminal end (AS 109-123).

Embodiment 2: producing an antibody specific for the epithelial endometrial hCG molecule (e β hCG) to β hCG epitope β 1 (AS 1-15).

Embodiment 3: producing monoclonal antibodies.

Embodiment 4: method for detecting e β hCG in bodily liquids

and tissue homogenates by means of ELISA.

Embodiment 5: composition of a test kits for detecting e β hCG in body liquids and tissue homogenates by means of ELISA.

Embodiment 6: method for determining optimal implantation conditions by determining endometrial hCG.

Embodiment 7: method for determining physiological endometrium states and for detecting fertilization dysfunctions in the menstrual cycle by determining ehCG.

Embodiments 8: method for retrograde determination of optimal implantation conditions by determining endometrial hCG in the menstrual blood.

Embodiment 9: methods for diagnosis for differentiation between maternal-decidual versus embryonic-trophoblastic dysfunctions in the case of miscarriage tendency and beginning miscarriage.

Embodiment 10: method for premature birth screening or diagnosis of onset of labor.

Embodiment 1:

For obtaining antibodies that recognize specifically endometrial- and decidual-translated e β hCG according to SEQ ID No. 10, in this embodiment the following deca-peptide (SEQ ID No. 12) is used as an antigen with high antigen activity out of the amino acid sequence range (SEQ ID No. 1) recommended in accordance with the invention for the antibody production relative to e β hCG epitope β 9:

P1: Cys - Asp - Asp - Pro - Arg - Phe - Gln - Ala - Ser -
Ser (SEQ ID No. 12)

This P1 is a synthetic peptide with 10 amino acids (AS) from the amino acid sequence 109-123 of the exon 3 of the endometrial variant of the $\beta 7$ and $\beta 6$ gene. This peptide differs from the known epitope $\beta 9$ near the C- terminal peptide (CTP- β hCG) of the trophoblastic β hCG subunit by one alanine (Ala) - instead of aspartate (Asp) - at position 8 of the peptide (amino acid position 117 in β hCG). The selected amino acid sequence differs considerably from the sequence of the β LH subunit (SEQ ID No. 11). Alternatively, other peptides with 7 to 15 amino acids out of the sequence area of the amino acid sequence area e β hCG epitope e $\beta 9$ (SEQ ID No. 1) can be used that contain alanine (Ala) at the position that corresponds to the amino acid position 117 in e β hCG (SEQ ID No. 10).

For obtaining control antibodies that recognize specifically the $\beta 5$, $\beta 8$, $\beta 3$ subunits of the known trophoblastic hCG (thCG) (SEQ ID No. 8), in this embodiment the following synthetic deca-peptide (SEQ ID No. 13) is used as an antigen of high antigen activity out of the amino acid sequence area (SEQ ID No. 2) in the epitope $\beta 9$ near the CTP- β hCG recommended in accordance with the present invention relative to β hCG epitope $\beta 9$:

K1: Cys - Asp - Asp- Pro - Arg - Phe - Gln - Asp - Ser - Ser
(SEQ ID No. 13)

The peptides P1 and K1 were produced by conventional solid-phase peptide synthesis, purified by gel filtration and ion exchange chromatography and specified by HPLC (23, 49).

The peptides P1 and K1 selected in accordance with the present invention from the amino acid sequence area for the β hCG epitope $\beta 9$ in this embodiment are bonded by means of the

EZ Antibody Production and Purification Kit, carboxylate reactive (Pierce Chemical Co., Rockford, IL) according to manufacturer's recommendations to the protein keyhole limpet hemocynain (KLH) as a carrier (53). In accordance with the recommended procedure, the peptides were bonded to bovine serum albumin (BSA) as a carrier for the subsequent ELISA. For producing polyclonal antibodies, five 12-week old rabbits (New Zealand white, each approximately having a weight of 2 kilograms) are each injected with different solutions of a total volume of 500 µl i.p. Rabbit #1 receives 200 µg KLH-bonded peptide P1 in 0.1 % NaCl with 1:1 adjuvant Specol (ID-DLO, Lelystad); rabbit #2 receives 500 µg KLH-bonded peptide K1 in 0.1 % NaCl with 1:1 adjuvant Specol; rabbit # 3 receives only 0.1 % NaCl with 1:1 adjuvant Specol. After 14 days, the injection is repeated with the same solution i. p. (booster shots), respectively. The last booster shot was applied three weeks after the first booster shot with the same solution. 14 days after the last booster shot the serum was removed, respectively. The sera were examined by ELISA according to standard conditions in regard to the presence of specific antibodies against P1.

For ELISA, the peptide P1 bonded to BSA was first applied in a concentration of 10 µg/ml in a coating buffer (0.1 mol/liter sodium carbonate/bicarbonate, pH 9.6) in 50 µl per well onto a MaxiSorp ELISA carrier (Nunc) and incubated for one hour at 37 °C. Parallel to this, a carrier (= negative control carrier) was coated accordingly with a solution of the BSA-bonded control peptide K1. The wells were subsequently washed five times with phosphate-buffered sodium chloride solution with addition of 0.1 % Tween 20 (PBS-T). Subsequently, 200 µl of a 10 % milk powder solution in PBS-T was added, respectively, and incubated for one hour at 37 °C and washed once with PBS-T. The thus prepared carriers were incubated with the immune sera, washed three times with PBS-

T, and incubated for 0.5 h with biotinylated anti-rabbit-IgG (Dako) as a secondary antibody and washed three times with PBS-T.

Subsequently, a 1:2,000 dilution of a streptavidin-peroxidase conjugate (Sigma) in PBS-T was added. After 30 minute incubation at 37 °C the carrier was washed twice with PBS-T and once with PBS and a substrate (100 µl) containing o-phenylene diamine hydrochloride was added. The yellow-brown color development was stopped after 5 minutes by adding 50 µl 2M H₂SO₄ and the optical density was determined at a wavelength of 490 nm (reference wavelength: 650 nm).

P1-specific antibodies could be detected only in rabbit #1 in the serum that were obtained seven days after injection but not in the serum before the injection as well as in none of the serum of rabbits #2 and #3. These experiments demonstrate that the peptide P1 is able to induce specific antibodies in rabbits.

For immunoaffinity chromatographic purification of the antibodies from the serum the peptide p1 is immobilized in accordance with manufacturer=s procedures for EZ1 Antibody Production and Purification Kits, Carboxy Reactive (Pierce) to a diamino dipropyl amine column (53). The serum, from which the specific antibodies were to be purified, was incubated for inactivation for 30 minutes at 56 °C. Subsequently, it was applied to the column and allowed to pass. Subsequently, the column was washed with 20 ml PBS and with 10 ml of a 0.5 mol/liter MgCl₂ solution. The specifically bonded antibodies were washed out by addition of 3 ml 3 mol/liter MgCl₂ followed by 3 ml of 4 mol/liter MgCl₂. The washed-out liquids were filled into dialysis hoses (Pierce) and dialyzed overnight at 4 °C against one liter of PBS. Subsequently, the protein content of the dialyzed preparations was determined by means of BCA protein kits

(Pierce), the purity was determined by SDS-PAGE and coomassie blue coloration as well as the specificity of the antibody preparation by means of ELISA.

Embodiment 2:

For the further amino acid differentiation between t β hCG and e β hCG in the β hCG epitope section β 1 at the amino acid positions +2 (Lys to Arg) and +4 (Pro to Met), an e β hCG specific antibody and a t β hCG specific control antibody are produced.

For generating antibodies that recognize specifically the endometrial and decidual translated e β hCG according to SEQ ID No. 10, in this embodiment the following synthetic peptide (SEQ ID No. 14) as antigen with high antigenicity is used from the amino acid sequence area (SEQ ID No. 3) recommended for the antibody preparation in accordance with the invention relative to the β hCG epitope e β 1:

P2: Ser - Arg - Glu - Met - Leu - Arg - Pro - Arg - Cys - Arg - Pro (SEQ ID No. 14)

This P2 is a synthetic peptide of the amino acid sequence area 1-15 in exon 2 that differs from the known epitope β 1 of the trophoblastic β hCG subunit in regard to two amino acid positions. The selected amino acid sequence P2 difference in this epitope section also significantly from the sequence of the β LH subunit (SEQ ID No. 11). Alternatively, other peptides with 7 to 15 amino acids of the sequence area of the amino acid sequence range e β hCG epitope e β 1 (SEQ ID No. 3) can be used which have argenin (Arg) and methionin (Met) at the positions corresponding to the amino acid positions 2 and 4 in e β hCG (SEQ ID No. 10).

For obtaining control antibodies that recognize specifically t β hCG (β 5, β 8, β 3), the same procedure in accordance with the adequate peptide (SEQ ID No. 15) selected as an example of the amino acid sequence of the β hCG gene β 5 of the epitope β 1 (SEQ ID No. 4) - amino acid sequence area AS 1 to 15 of the t β hCG (SEQ ID No. 8) is carried out:

K2: Ser - Lys - Glu - Pro - Leu - Arg - Pro- Arg - Cys - Arg
- Pro (SEQ ID No. 15)

The immunization of the rabbits was equally successful with P2 and K2 as in the case of P1 and K1. The e β hCG-specific antibodies were also obtained with P2 that showed no cross-reactivity for K2 or t β hCG and also no cross-reactivity with β LH.

Embodiment 3:

Producing monoclonal antibodies (mAb) is carried out in accordance with the hybridoma preparation well described in the literature for ISOBM-mAb h54, 264, 277, 278, 287, 282, and 313 for epitope β 8, FB-12 and 280 for epitope β 9, and 256, 274, and 284 for epitope β 1 with carrier-bonded synthetic β hCG peptide sequences (18, 20-24, 45-48), wherein in the peptide sequences the amino acids at position +2, +4, and +117 were exchanged for the endometrial hCG (e β hCG). The preparation of ISOBM-mAb showed that the preparation of hybridoma which secret antibodies of the desired β hCG specificity can be repeated reliably (18, 24, 45-48).

For hybridoma preparation, the carrier-bonded synthetic e β hCG specific peptide sequences P1 and P2 (SEQ ID Nos. 12 and 14) as well as the control peptides K1 and K2 (SEQ ID No. 13 and 15) were used.

The preparation of the monoclonal antibodies for P1 will be explained in the following in more detail:

The immunization was realized in BALB/c mice. For this purpose, for each mouse approximately 1 mg of purified carrier-bonded peptide was required.

Immunization: eight female BALB/c mice (Roche, Institut für Biologisch-Medizinische Forschung, Basel, Switzerland), six to eight weeks old, are immunized by means of the KLH-bonded peptide P1 produced in accordance with embodiment 1 for each animal according to the following protocol (18, 20, 24, 45-51): The first immunization was realized by subcutaneous injection of 50-150 µg β hCG peptide immunogen on the carrier for each animal in complete Freund's adjuvant. The further immunizations were carried out every other day by injection of the same amount of immunogen in incomplete Freund's adjuvant. On day 17 the mice received an intraperitoneal immunization again with 50-150 µg of the antigen in PBS support for each animal, respectively. The immun sera are tested with the hCG-POD system in regard to released antibodies (ELISA in embodiment 1). The mice with the high hCG antibody immune responses (approximately 3) are boosted again with 50-150 µg β hCG immunogen and were assigned for fusion after three days.

Fusion: after immunization from the knee joint lymph nodes and spleen of mice immunized in this way the splenocytes (B-lymphocytes) are isolated and fused with cells of the mouse myeloma cell line P3-X63-Ag8.653 (American Type Culture Collection) according to the method of Köhler and Milstein (51) as described in Kovalevska (47). The ratio of splenocytes to myeloma cells in this connection is 4:1 to 6:1. RPMI-1640 with 10 % fetal calf serum (FCS) or polyethylene glycol 1500 (Sigma) is used as a fusion medium.

The immun serum of the selected mice is collected as positive control.

selection of fused cells (hybridoma cells): The generated hybridoma cells after fusion are separated from the myeloma cells that have not undergone fusion, are distributed onto microtiter carriers and, together with peritoneal ascites cells of the mouse are cultivated for a week in a RPMI culture medium that contains hypoxanthine, aminopterin, and thymidine (HAT) with 10 % FCS (46-50). Half of the medium was replaced every three days. On the days 12-14 after fusion a portion of the liquid above the culture of the wells was tested in regard to the presence of hCG antibodies by ELISA (screening of the oligoclones).

The screening of the oligoclones was realized by ELISA as described in embodiment 1 with the difference that in place of the biotinylated anti-rabbit IgG a biotinylated anti-mouse IgG antibody (Dako) was used.

The liquid above the culture of 10 % of the screened wells show with ELISA carrier on which P1 was immobilized but not with the negative control carrier, a color reaction in ELISA.

Thus, 10 % of the obtained oligoclones recognize therefore specifically the peptide P1 but not K1.

Three especially productive Ig-positive cell clones, P1.1, P1.2, and P1.3, show an especially high antibody titer with the desired ehCG specificity and were selected for the further subcloning.

Subcloning: The selected oligoclones are now subcloned to monoclonality (50). In this connection, positive clones were selected and multiplied in vitro (cloning by limiting dilution method). The isolated colonies were tested again with ELISA. The positive-testing clones were used for the

next cycle of cloning. Three cycles of cloning are required in order to obtain specific stable clones. They were used for the formation of 100 ml liquid with the monoclonal antibodies.

The molecular hCG antibodies were subsequently purified by affinity chromatography with the protein A-sepharose purification system for monoclonal antibodies (Biorad). The purity of mAb was tested by SDS polyacrylamide gel electrophoresis and subsequently the protein concentration was determined (18, 52). The specificity of the antibodies was assayed against the heterodimer $\alpha\beta$ hCG molecule with e β hCG as a β subunit as well as against the indicated peptide P1 in the above described ELISA.

The monoclonal antibodies produced in this way by immunization, isolation, hybridization, and purification are stored at -20 °C.

The production of monoclonal antibodies with the peptide P2 was carried out in accordance with the same procedure and lead to comparable results. With P2 e β hCG specific antibodies were also obtained that did not exhibit cross-reactivity for K2 or t β hCG.

Embodiment 4:

For detecting the epithelial endometrial and decidual hCG (ehCG) in body liquids and tissue homogenate, the endometrial or decidual β hCG antibodies that are specific for β hCG epitope β 8 and β hCG epitope β 1 and prepared in accordance to embodiments 1 to 3 are adsorbed on microtiter plates and test systems on the basis of ELISA technology are developed. Adequate ELISA arrangements are used as a control system by employing comparable trophoblastic β hCG (thCG) antibodies of

the respective β hCG epitopes β 1 and β 8 (18, 21-24, 47).

Sandwich ELISA: In accordance with embodiment 3 the immune-purified monoclonal e β hCG antibodies specific to P1 and P2 (e β hCG) as well as K1 and K2 (t β hCG) are adsorbed as initial antibodies in a solution of 100 μ l/well of MaxiSorp ELISA carriers (Nunc, 96 wells) (10 μ g/ml in 200 mM bicarbonate buffer, pH 9.6, 1 hour at 37 $^{\circ}$ C or overnight at 4 $^{\circ}$ C). The wells are subsequently washed twice with washing buffer (10 mM PBS, pH 7.2 with 0.05 % Tween 20) and incubated for one-hour with blocking buffer (1 % BSA in PBS pH 7.2).

Subsequently, incubation (100 μ l, one hour, 37 $^{\circ}$ C, respectively) with the serum in which the endometrial hCG (e β hCG) is to be assayed. The serum is diluted for this purpose 1:10 to 1:1,000 in blocking buffer. As a standard series of hCG determination additionally the synthetic peptides P1, P2 (specific to endometrium) and K1 and K2 (specific to trophoblast) are incubated in six different concentration stages between 0 and 1000 ng/ml.

When hCG is present in the employed samples, it will bind on the immobilized endometrial or trophoblastic specific antibodies of the wells. The assay system employs after respective washing steps the second biotinylated anti- β hCG-antibody that binds as a sandwich to the immobilized solid phase β hCG antibody/ β hCG complex. As a second monoclonal hCG/ β hCG antibody that recognizes the endometrial as well as the trophoblastic total molecule hCG and its β -subunit, in this embodiment a biotinylated antibody specific for the hCG β 2 epitope (INN-22 Serotoc) is used. After incubation at room temperature and additional washing steps for removing excess enzyme-bonded β hCG antibody, the same process as in embodiment 1 is carried out. The detection is initiated with a 1:2,000 dilution of the streptavidin preoxydase conjugate

(Sigma) in PBS-T.

After incubation for 30 minutes at 37 °C, the carrier was washed twice with PBS-T and once with PBS and a substrate (100 µl) containing o-phenylene diamino hydrochloride was added. The yellow-brown color development was stopped after five minutes by adding 50 µl 2 M sulfuric acid and the optical density was determined at a wavelength of 490 nm (reference wavelength: 650 nm).

Embodiment 5

A test kit for specific detection of endometrial respectively decidual hCG and its β hCG subunit (e β hCG) in body liquids and tissue homogenates by ELISA contains, for example, the following components:

1. an ELISA carrier (10 µg per well, respectively) that is precoated with e β hCG-specific antibody clone P1.2 of embodiment 3 (specific for e β hCG expressed in the endometrium and decidua; does not recognize t β hCG);
2. six dilutions of the peptide P1 as a standard series (0, 10, 50, 100, 500, 1,000 µg/ml);
3. washing buffer PBS-T (10 mM PBS, pH 7.2 with 0.05 % Tween 20);
4. blocking buffer (1 % BSA in PBS, pH 7.2);
5. biotinylated total hCG/ β hCG antibody as second hCG antibody specific for the hCG β 2 epitope (INN-22 Serotec);
6. streptavidin-HRP conjugate (Dako);
7. PBS (Dako);
8. o-phenylene diamine as substrate;
9. 2 M sulfuric acid as a stop solution.

As an alternative to component 5, the test kit contains, for

example, as a second hCG antibody a biotinylated antibody specific for the hCG β 4 epitope (INN-24, Serotec).

An adequate test kit as a control kit or for specific determination of the trophoblastic hCG in body liquids or homogenized tissue samples contains, for example, the above-mentioned components 3 to 9, and, instead of component 1, a t β hCG-specific antibody obtained by immunization with K1, and, instead of component 2, appropriate dilutions of the control peptide K1 as a standard series.

with the kit for specific detection of the e β hCG the quantification and evaluation of specific epithelial endometrial hCG secretion (e β hCG) in body liquids and cell or tissue homogenates of the early to middle secretion phase of the menstrual cycle, optimal implantation conditions (embodiment 6) as well as possible fertilization dysfunctions (embodiment 7) can be detected - prospective as well as retrograde - in consideration of endometrial diagnostics and therapy control.

Embodiment 6:

For the prospective diagnostics of embryo receptivity in the early secretion phase of the current cycle from the female patient wanting a child, for example, at the middle of the cycle a Pap smear with cervical secretion of the cervical channel or a vaginal Pap smear with vagina secretion is taken for diagnostic evaluation of implantation conditions. This Pap smear is examined with regard to the present beginning or already ongoing expression or secretion o β hCG by means of the ELISA disclosed in embodiment 4. In this way, it is also possible to provide information in regard to the quality of the secretory transformation and the expected receptivity of the endometrium.

In the context of in-vitro fertilization two days after follicle puncture a cotton swab is shortly inserted into the cervix or the vaginal pap smear is taken and by means of ELISA disclosed in connection with embodiment 4 the activation of e β hCG is diagnosed. A positive e β hCG result signalizes a receptive endometrium and the embryo still being cultured can be transferred one or two days later. Should the test be negative, the embryo will be cryo-preserved and will be flushed into the uterine cavity during the next cycle that was determined to be positive for e β hCG. In this way, decisions in regard to embryo transfer or insemination of hormonally stimulated female patients for the actual or the subsequent cycle can be made. In addition to the cervical secretion it is also possible to employ sample material (tissue, cells, perfusate) of other epithelial organs such as the oral mucous membrane or vaginal mucous membrane.

Since all epithelial organs are subject to the cycle more or less they can also be incorporated into the examination.

Embodiment 7:

with this embodiment, in the female patients physiological or pathological endometrium states can be detected and possible fertilization dysfunctions under the aspect of endometrial hCG diagnostics and therapy control can be detected and evaluated during the actual cycle or the subsequent cycle.

For this purpose, a Pap smear of the cervical channel with cervical secretion or a vaginal Pap smear with vaginal secretion is taken from the female patient for diagnostic evaluation during the secretory phase of the endometrial transformation, primarily during the middle secretion phase about the 20th to 24th day of the cycle.

This Pap smear is examined with regard to the present beginning or ongoing expression or secretion of $e\beta hCG$ by means of ELISA described in embodiment 4. In this way, information in regard to the lack of, low-value or high secretory transformation of the endometrium and the quality of the expected receptivity of the endometrium can be made for the female patient.

The presence of unequivocally measurable $e\beta hCG$ on the 20th to 24th day of the cycle signals a healthy endometrium transformed properly with regard to time and function. At the same time, this is an expression of unhindered interaction between hypothalamus and pituitary gland, the ovaries and the uterus. With the presented method of a Pap smear of patients for examination of the $ehCG$ in body liquids and cell and tissue homogenates, the diagnostics and therapy control of the uterus function can be performed. For this $ehCG$ determinations with the above-mentioned methods, it is also possible to employ the endometrium sampled by curettage according to diagnostic indication.

Embodiment 8:

The removal of menstrual blood from female patients after unstimulated, stimulated or disturbed cycle represents an important, simple and up to now unused method for retrograde implantation diagnostics in order to detect information for the secretory transformation of the endometrium of the previous cycle and optionally information for the receptivity of the subsequent cycle. This non-invasive method can supplement or replace the invasive method of diagnostic sample curettage with regard to its information contents.

The menstrual blood as a result of the endometrial desquamation is used like peripheral blood for separation of

cell material and stroma for the direct measurements of endometrial hCG secretion (ehCG) with specific ehCG antibodies in an ELISA test in accordance with embodiment 4.

The menstrual blood is taken after a spontaneous cycle, after hormone therapy, after IVF and ET without successful implantation as well as for proposed diagnostics of the cycle in the case of females wanting children and in the case of IUD patients, myoma and endometriosis. In this connection, a parallel analysis of peripheral blood is provided at the same time for exclusion of an also increased serum value of ehCG.

The epithelial and stroma cell material of the endometrial tissue after desquamation that has been separated from the menstrual blood is used like the menstrual plasma by means of ELISA tests for evaluating the expression and secretion of endometrial hCG in the preceding cycle.

Embodiments 9:

The diagnostics for a differentiation between maternal-decidual versus embryonal-trophoblastic dysfunctions in the case of miscarriage tendency and beginning of miscarriage is based on the fact that eβhCG is expressed in the maternal-decidual tissue of pregnancy as in the secretory endometrium. In the embryonal-trophoblastic tissue of the placenta trophoblastic hCG is expressed and translated. The hCG concentrations of the peripheral blood in the pregnancy show a secretion maximum in the first trimester and are significant for the second and third trimesters.

In this embodiment, an application is demonstrated in which hCG differentiated during pregnancy as endometrial/decidual hCG (ehCG) and trophoblastic hCG (ThCG) can be detected in peripheral blood but also vaginal or cervical secretions of a Pap smear, in the released amniotic fluid in the case of

perforated or burst amniotic sac, in the lochia blood as well as in other epithelial secretions and/or their cell and tissue homogenates by ELISA or in quantitative real-time RT-PCR.

In the case of an impending miscarriage, characterized by the beginning of uterine bleeding, a therapeutic poly-pragmatic approach is used because first the reason of the dysfunction is unclear. In the case of an impending miscarriage by differentiation of embryonic hCG (ehCG) and the trophoblastic hCG (thCG) it is possible to differentiate between a maternal-decidual versus trophoblastic-embryonic cause of the dysfunction.

For this purpose, serum of the patient or the above mentioned other bodily liquids and cell and tissue homogenates are taken and examined by means of the ELISA kits developed with the present invention in regard to ehCG and/or thCG (embodiment 4). It is also possible to detect thCG by a conventional commercially available kits that are recommended for common placenta hCG measurements during pregnancy (DPI, Abbott, Serono, Roche, Baxter). A low ehCG value indicates a beginning decidual insufficiency while a comparatively low thCG value signalizes a dysfunction of the fetus/placenta unit. While the first dysfunction can be treated, in the case of the dysfunction of the thCG secretion it must be determined whether a therapy is possible and expedient.

Also, the prognosis of an impending miscarriage can be detected in the blood. For this purpose, miscarriage blood is taken with a speculum from the rear vaginal cavity and a determination of ehCG with the ELISA kit according to the invention is performed. In the case of minimal bleeding, blood or bloody cervix mucus can be taken by a cotton swap and can be tested by ELISA test (embodiment 4) and/or

quantitative real-time RT-PCR with regard to e β hCG. A high ehCG result indicates a decidual dysfunction. In the case of very high ehCG values, a miscarriage that cannot be treated is to be expected.

The method of this embodiment can also be used as a therapy control in the treatment of decidual dysfunctions.

Embodiment 10:

Screening for premature delivery or diagnostics of the onset of labor is based on that the embryonic hCG (ehCG) in the genital tract is increased before premature birth while ehCG in the serum is lowered. For this reason, the above-mentioned method can be used for screening for premature birth. The same pattern is also found at the beginning of the birthing process at the end of the pregnancy.

For premature birth screening or for diagnosis of beginning of the birth, secretions or cells are removed from the genital tract (cervix, rear vaginal cavity) of the female patients. In the secretion, ehCG is determined with the above-mentioned ELISA test; in the case of removal of cells, the ehCG β 7 expression is determined in the secretion by means of quantitative real-time RT-PCR. An increased ehCG result in the secretion like a reduced ehCG β 7 in the cells of the genital tract signals the beginning of a premature birth.

Moreover, premature birth screening is also possible a serum examination. In this connection, serum of the patient is obtained and ehCG is determined. At low or dropping ehCG values, a premature birth is to be expected.

Instead of the ELISA test described in the embodiments, it is

also possible to employ a quantitative detection of the ehCG gene expression by real-time RT-PCR for detecting the e β hCG concentration in the tissue samples.

List of Abbreviations:

In the description the following abbreviations are being used:

α hCG	alpha-subunit of human chorionic gonadotrophin
β hCG	beta-subunit of human chorionic gonadotrophin
BSA	bovine serum albumin
CTP	C-terminal peptide
EDTA	ethylene diamine tetra acetate
ET	embryo transfer
E β hCG	endometrial beta-subunit of human chorionic gonadotrophin
ehCG	endometrial human chorionic gonadotrophin (e β hCG + α hCG)
hCG	human chorionic gonadotrophin
IgG	immunoglobulin gamma
ISOBM	International Society of Oncodevelopmental Biology and Medicine
IUD	intrauterine device
IVF	in-vitro fertilization
KLH	keyhole limpet hemocyanin hemocyanin
PBS-T	phosphate buffered saline solution with 0,1 % Tween 20 added
ELISA	enzyme-linked immunosorbent assay
mAb	monoclonal antibody
MEIA	microparticle enzyme immunoassay
mM	mMol/liter
PBS	phosphate buffered amine solution
t β CG	throphoblastic beta-subunit of human chorionic gonadotropin

Cited Non-Patent Literature:

- (1) J.C.Pierce, T.F.Parsons, *Annu.Rev.Biochem.*, **50** (1981) 465-495
- (2) P.A.Rothman, V.A.Chao, M.R. Taylor et al., *Mol.Reprod.Dev.*, **33** (1992) 1-6
- (3) S.Dirnhofner, M.Hermann, et al., *J.Clin.Endocrinol.Metab.*, **81** (1996) 4212-4217
- (4) Z.M.Lei, P.Toth, C.V.Rao und D.Pridham, *J.Clin.Endocrinol.Metab.*, **77** (1993) 863-972
- (5) T.Yokotani, T.Koizumi, R.Taniguchi et al., *Int.J.Cancer*, **71** (1997) 539-544
- (6) P.Berger, W.Kranewitter, S.Madersbacher et al., *FEBS Lett.*, **343** (1994) 229-233
- (7) D.Bellet, V.Lazar, I.Bieche et al., *Cancer Res.*, **57** (1997) 516-523
- (8) I.Marcilliac, F.Troalen, J.-M.Bidart et al., *Cancer Res.*, **52** (1992) 3901-3907
- (9) H.Alfthan, C.Haglund, J.Dabek et al., *Clin.Chem.*, **38** (1992) 1981-1987
- (10) V.Lazar, S.G.Diez, A.Laurent et al., *Cancer Res.*, **55** (1995) 3735-3738
- (11) P.N.Span, C.M.G.Thomas, J.J.Heuvel et al., *J.Endocrinol.*, **172** (2002) 489-495
- (12) M.Lundin, S.Nordling, J.Lundin et al., *Int.J.Cancer*, **95** (2001) 18-22
- (13) K.Hotakainen, B.Ljungberg, A.Paju et al., *Brit.J.Cancer*, **86** (2001) 185-189
- (14) D.S.Hoon, T.Sarantou, F.Doiet al., *Int.J.Cancer*, **69** (1996) 369-374
- (15) M.Bo und I.J.Boime, *J.Biol.Chem.*, **267** (1992) 3179-3184
- (16) K.Talmdge, N.C.Vamvakopoulos und J.C.Fiddes, *Nature*, **307** 1984) 37-40
- (17) P.Policastro, C.Ovitt, M.Hoshina et al., *J.Biol.Chem.*, **258** (1983) 11492-11499

- (18) P.Berger, C.Sturgeon, J.M.Bidart et al., *Tumor Biol.*, **23** (2001) 1-38
- (19) J.M.Bidart, S.Birken, P.Berger et al., *Scand.J.Clin.Lab.Invest.*, **216** (1993) 118-136
- (20) P.Berger, J.M.Bidart, P.S.Delves et al., *Mol.Cell Endocrinol.*, **125** (1996) 33-43
- (21) S.Dirnhofer, S.Madersbacher, J.M.Bidart et al., *J.Endocrinol.*, **141** (1994) 153-162
- (22) P.Berger, R.Klieber, W.Panmuong et al., *J.Endocrinol.*, **125** (1990) 301-309
- (23) J.M.Bidart, F.Troalen, C.J.Bohuon et al., *J.Biol.Chem.*, **262** (1987) 15483-15489
- (24) J.M.Bidart, D.H.Bellet, G.F.Alberici et al., *Mol.Immunol.*, **24** (1987) 339-345
- (25) P.K.Hotakainen, E.M.Serlachius et al., *Mol.Cell.Endocrinol.*, **162** (2000) 79-85
- (26) A.K.Miller-Lindholm, C.J.Labenz, J.Ramey et al., *Endocrinology*, **138** (1997) 5459-5465
- (27) S.Madersbacher, C.Kratzik, R.Gerth et al., *Cancer Res.*, **54** (1994) 5096-5100
- (28) R.Oyasu, L.Nan, P.Smith et al., *Arch.Pathol.Lab.Med.*, **119** (1994) 715-717
- (29) L.A.Cole, *Clin.Chem.*, **43** (1997) 2233-2243
- (30) L.A.Cole, *J. Reprod. Med.*, **43** (1998) 3-10
- (31) L.A.Cole, K.M.Rinne, S.Shahabi et al., *Clin. Chem.*, **45** (1999) 313-314
- (32) A.Kardana, M.M.Elliott, M.A.Gawinowicz et al., *Endocrinology*, **129** (1991) 1541-1550
- (33) S.Birken, A.Krichevsky, J.O'Connor et al., *Endocrine*, **10** (1999) 137-144
- (34) A.Krichevsky, S.Birken, J.O'Connor et al., *Endocrinology*, **134** (1994) 1139-1145
- (35) G.Kovalevskaya, S.Birken, T.Kakuma et al., *J. Endocrinol.*, **161** (2000) 99-109
- (36) P.Mock, G.Kovalevskaya, J.F.O'Connor et al., *Hum. Reprod.*, **15** (2000) 2209-2214

- (37) P.Mock, P.Bischof, R.Rivest et al., *Hum. Reprod.*, **13** (1998) 2629-2632
- (38) M.Seppälä, E.-M.Rutanen, et al., *J.Clin.Endocrinol. Metab.*, **47** (1978) 1216-1219
- (39) R.W.Sharpe, W.Wrixon, et al., *J.Clin.Endocrinol.Metab.*, **45** (1977) 496-499
- (45) G.Kovalevskaya, S.Birken, T.Kakuma et al., *Clin.Chem.*, **45** (1999) 68-77
- (46) C.Stähli, T.Staehelin, V.Miggiano et al., *J.Immunol.Method.*, **32** (1980) 297-304
- (47) G.Kovalevskaya, S.Birke, J.O'Connor et al., *Endocrine*, **3** (1995) 881-887
- (48) J.B.Conde, A.B.Moreno, C.A.Bas, *Hybridoma and Hybridomics* **21** (2002) 381-384
- (49) R.B.Marrifield, *J.Am.Chem.Soc.*, **85** (1963) 2149-2154
- (50) A.M.Krieg, *Am.Rev.Immunol.*, **20** (2002) 709-760
- (51) G.Köhler, C.Milestein, *Nature*, **256** (1975) 495
- (52) S.Madersbach, P.Berger, *Methods*, **21** (2000) 41-50
- (53) Pierce, Rockford, USA: EZ Antibody Production and Purification Kit, Carboxy Reactive
- (54) L.A.Cole, *Gynecol.Oncol.*, **71** (1998) 325-329